ALK Announces Edward Jordan as New Executive Vice President
In a significant leadership move, ALK (Copenhagen: ALK B / LSE: 0OIR) has appointed Edward Jordan as the Executive Vice President (EVP) and head of Commercial Operations in North America. This strategic decision aims to bolster the company’s leadership team, reflecting its commitment to enhancing execution in the key markets of Europe and North America.
Edward Jordan’s Extensive Experience
Edward Jordan joins ALK with over 30 years of experience in the biopharmaceutical industry. His impressive resume includes prominent roles at well-respected firms such as Merck (Schering-Plough), Teva Pharmaceuticals, and DBV Technologies. Throughout his career, he has developed a deep expertise in allergy and immunology, specifically contributing to the development of popular allergy medications like Claritin and Clarinex, as well as innovative solutions like Viaskin.
Jordan's background positions him as an asset to ALK. His knowledge of the emerging food allergy market alongside his proven track record in commercial strategy, product launches, and market development will be invaluable as ALK seeks to strengthen its foothold in North America.
Leadership Insights from ALK’s CEO
Peter Halling, President and CEO of ALK, expressed enthusiasm about Jordan’s appointment. He highlighted the importance of commercial execution, citing recent successful launches of allergy immunotherapy tablets for children and nasal adrenaline sprays. Halling emphasized that Jordan's vast experience in driving commercial growth and his understanding of the North American market align perfectly with ALK’s strategic objectives.
Halling stated, “Ed joins ALK with extensive experience in leading commercial growth, commercialising therapies, and advancing care for patients with allergic and immunologic conditions. We are very pleased to welcome Ed to ALK’s Executive Leadership Team where his pharma and market expertise will be greatly appreciated.”
Jordan’s Vision for ALK
Upon his selection, Jordan expressed his excitement about joining ALK at this crucial phase in its growth trajectory. He remarked on ALK’s strong presence in the allergy sector and their commitment to treating allergy and associated conditions effectively. Jordan looks forward to leveraging his experience to enhance commercial operations, thereby expanding access to ALK’s innovative products across North America.
Executive Leadership Team at ALK
Following this recent appointment, ALK’s Executive Leadership Team now includes:
- Peter Halling, President & CEO
- Claus Steensen Sølje, EVP & CFO
- Henriette Mersebach, EVP, R&D
- Christian G. Houghton, EVP, Product Supply
- Flora Beiche-Scholz, EVP, Commercial Operations Europe
- Edward Jordan, EVP, Commercial Operations North America
- Lika Thiesen, EVP, Global People & Organisation
- Jacob Glenting, SVP, Global Strategy & Corporate Development and Global Marketing
- Jan Engel, SVP, Global Quality
About ALK
ALK is a premier global specialty pharmaceutical company dedicated to the research and development of innovative treatments for allergy and allergic asthma. With its headquarters in Hørsholm, Denmark, ALK employs a workforce of approximately 2,800 individuals globally. The company has a significant presence in the marketplace through the manufacture and provision of allergy immunotherapy (AIT) treatments, acute anaphylaxis therapies, and a suite of support services for healthcare providers and allergy sufferers.
For those interested in learning more about ALK or discussing potential inquiries, please reach out to:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media Contact: Maiken Riise Andersen, tel. +45 5054 1434
Frequently Asked Questions
What is the new role of Edward Jordan at ALK?
Edward Jordan has been appointed as the Executive Vice President and head of Commercial Operations in North America at ALK.
How many years of experience does Edward Jordan have?
Edward Jordan brings over 30 years of biopharmaceutical experience, including significant roles in major pharmaceutical companies.
What is ALK’s primary focus?
ALK specializes in allergy and allergic asthma treatments, providing innovative allergy immunotherapy solutions and related services.
Who is ALK’s CEO?
Peter Halling serves as the President and CEO of ALK, overseeing the company's strategic direction and management.
Where is ALK headquartered?
ALK is headquartered in Hørsholm, Denmark, and employs approximately 2,800 people globally.
